Rovi rolls out Becat enoxaparin in Europe
Introducing its Enoxaparin Becat biosimilar in both Spain and France during September this year – in the latter market through partner Biogaran – enabled Laboratorios Farmacéuticos Rovi to report turnover from the low molecular weight heparin (LMWH) of €7.8 million (US$8.9 million) in the third quarter, and €16.7 million in the first nine months, of this year. The Spanish firm has also just rolled out Becat in Austria and Latvia.
You may also be interested in...
Spain’s Laboratorios Farmaceuticos Rovi has set out why it remains confident in its prospects for its Becat (enoxaparin) biosimilar to Sanofi’s Lovenox/Clexane while providing an update for the firm’s Doria once-a-month injectable formulation of risperidone.
Rovi has started to market its enoxaparin biosimilar directly in Portugal as the Spanish company prepares to market teriparatide in its domestic market through a tie-up with Teva.
The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.